CRL Price Prediction Next Week
Analysis and Insights
News and Analyst Upgrades:
Charles River Laboratories (CRL) has recently received upgrades from Citi and Redburn Atlantic. Citi upgraded CRL to Neutral from Sell, raising the price target to $175, citing that the stock adequately reflects concerns and headwinds are modeled by the Street. Redburn Atlantic also upgraded CRL to Neutral with a price target of $188, noting stabilized demand in the Discovery and Safety segment.
Technical Indicators:
- RSI (14): 62.35 (Neutral)
- MACD: Positive (0.45), indicating bullish momentum.
- SMA (20, 50, 60, 200): CRL is trading above these moving averages, signaling bullish strength.
- Fibonacci Levels: Resistance at $178.38 (R1) and $184.20 (R2).
Current Price Action:
The stock is trading at $178.3, near the lower Bollinger Band, suggesting potential upside.
Prediction and Recommendation:
Based on the upgrades and technical indicators, CRL is expected to test the Fibonacci resistance level at $178.38.
Predicted Price: $178.38
Recommendation: Buy
CRL Similar Chart Price Prediction
The price of CRL is predicted to go up 5.5%, based on the high correlation periods with EVN. The similarity of these two price pattern on the periods is 93.02%.
CRL
EVN
Up: 5.5%Similarity: 93.02%
CRL Revenue Forecast
CRL EPS Forecast
CRL FAQs
What is CRL revenue forecast for next quarter？
What is CRL eps forecast for next quarter？
CRL VS S&P500
Charles River's reputation for quality and scientific expertise supports its leading position in the research model and preclinical trial markets.
The company's contract research business should benefit from robust biotech demand and funding.
The high-margin manufacturing support segment should boost earnings for the company as it grows.
CRL Analyst's Forecast
Patrick Donnelly
Citigroup
Strong Sell → Hold
2025-03-04
Price Target
$155 → $175
Upside
+6.51%
Citi analyst Patrick Donnelly upgraded Charles River to Neutral from Sell with a price target of $175, up from $155. The firm thinks headwinds from the company's large pharma customer group with regard to Inflation Reduction Act caution and its pipeline restructuring are now well understood by investors. Citi, however, does not upside to estimates, and believes Charles River's Discovery and Safety Assessment segment will continue to face price and mix headwinds throughout the year.
Eric Coldwell
Baird
Hold
2025-02-20
Price Target
$177 → $173
Upside
+6.63%
Luke Sergott
Barclays
Hold
2025-02-20
Price Target
$166 → $160
Downside
-1.39%
